Oxymetazoline Hydrochloride Patent Expiration

Oxymetazoline Hydrochloride is used for reducing persistent facial redness associated with rosacea in adult patients. It was first introduced by Bayer Healthcare Llc in its drug Ocuclear on May 30, 1986. Other drugs containing Oxymetazoline Hydrochloride are Rhofade, Visine L.R., Upneeq. 5 different companies have introduced drugs containing Oxymetazoline Hydrochloride.


Oxymetazoline Hydrochloride Patents

Given below is the list of patents protecting Oxymetazoline Hydrochloride, along with the drug name that holds that patent and the company name owning that drug.

Filter patents by

NEW
Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Upneeq US10799481 Compositions and methods for treating ocular disorders Dec 16, 2039 Rvl Pharms
Upneeq US10814001 Oxymetazoline compositions Dec 16, 2039 Rvl Pharms
Upneeq US10898573 Oxymetazoline compositions Dec 16, 2039 Rvl Pharms
Upneeq US10940138 Compositions and methods for treating ocular disorders Dec 16, 2039 Rvl Pharms
Upneeq US11103482 Oxymetazoline compositions Dec 16, 2039 Rvl Pharms
Upneeq US11311515 Oxymetazoline compositions Dec 16, 2039 Rvl Pharms
Upneeq US11324722 Compositions and methods for treating ocular disorders Dec 16, 2039 Rvl Pharms
Upneeq US11541036 Oxymetazoline compositions Dec 16, 2039 Rvl Pharms
Upneeq US11701343 Compositions and methods for treating ocular disorders Dec 16, 2039 Rvl Pharms
Rhofade US10335391 Stabilized oxymetazoline formulations and their uses Jun 11, 2035 Mayne Pharma
Rhofade US10751325 Stabilized oxymetazoline formulations and their uses Jun 11, 2035 Mayne Pharma
Rhofade US11517560 Stabilized oxymetazoline formulations and their uses Jun 11, 2035 Mayne Pharma
Rhofade US12350255 Stabilized Oxymetazoline Formulations And Their Uses Jun 11, 2035 Mayne Pharma
Rhofade US9974773 Stabilized oxymetazoline formulations and their uses Jun 11, 2035 Mayne Pharma
Rhofade US8883838 Pharmaceutical cream compositions and methods of use Dec 01, 2031 Mayne Pharma
Upneeq US10912765 Compositions and methods for non-surgical treatment of ptosis Aug 26, 2031 Rvl Pharms
Upneeq US8357714 Compositions and methods for non-surgical treatment of ptosis Aug 26, 2031 Rvl Pharms
Upneeq US9867808 Compositions and methods for non-surgical treatment of Ptosis Aug 26, 2031 Rvl Pharms
Rhofade US7812049 Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists May 02, 2028 Mayne Pharma
Rhofade US8420688 Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists Aug 02, 2024

(Expired)

Mayne Pharma
Rhofade US8815929 Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists Jan 22, 2024

(Expired)

Mayne Pharma



A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Oxymetazoline Hydrochloride's patents.

Given below is the list recent legal activities going on the following patents of Oxymetazoline Hydrochloride.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 8th Yr, Small Entity 13 Jul, 2025 US9867808
Expire Patent 19 May, 2025 US8420688
Payment of Maintenance Fee, 4th Yr, Small Entity 30 Jan, 2025 US11103482
Maintenance Fee Reminder Mailed 02 Dec, 2024 US8420688
Payment of Maintenance Fee, 4th Yr, Small Entity 09 Sep, 2024 US10940138
Payment of Maintenance Fee, 4th Yr, Small Entity 07 Aug, 2024 US10912765
Payment of Maintenance Fee, 4th Yr, Small Entity 24 Jul, 2024 US10898573
Payment of Maintenance Fee, 12th Yr, Small Entity 17 Jul, 2024 US8357714
Payment of Maintenance Fee, 4th Yr, Small Entity 12 Apr, 2024 US10814001
Payment of Maintenance Fee, 4th Yr, Small Entity 12 Apr, 2024 US10799481


Oxymetazoline Hydrochloride's Family Patents

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List

Oxymetazoline Hydrochloride Generic API Manufacturers

Only one generic application has been filed for Oxymetazoline Hydrochloride.

Given below is the list of companies who have filed for Oxymetazoline Hydrochloride generic, along with the locations of their manufacturing plants worldwide.